Generate Biomedicines, Inc.

Generate Biomedicines, Inc. is a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development. Its primary purpose is to program biology to generate optimal therapeutics for significant impact on human health, leveraging the Generate Platform, a therapeutic area and protein modality agnostic system. This platform integrates computational innovation with scalable biohardware in a fully-integrated design–build–test–learn loop to create proprietary data and differentiated molecular solutions. It engineers proteins against therapeutic targets, either from existing references or through de novo design, addressing challenges beyond traditional technologies. The platform has advanced computationally engineered proteins into human clinical testing, including GB-0895, an investigational long-acting anti-TSLP monoclonal antibody enrolling patients in pivotal Phase 3 trials for severe asthma. Generate Biomedicines, Inc. also advances oncology product candidates toward clinical stages. Operating at the intersection of machine learning, biological engineering, and medicine, the company focuses on protein-based modalities across multiple disease areas to transform drug discovery into systematic drug generation. Founded in 2018 and headquartered in Somerville, Massachusetts, it plays a key role in advancing AI-driven biotherapeutics in the healthcare sector.